Bulletin
Investor Alert

Intra-Cellular Therapies Inc.

NAS: ITCI

GO
/marketstate/country/us

After Hours

/zigman2/quotes/209441868/composite

$

27.01

Change

-0.37 -1.35%

Volume

Volume 4,677

Sep 23, 2020, 7:39 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/209441868/composite

Today's close

$ 28.41

$ 27.38

Change

-1.03 -3.63%

Day low

Day high

$27.28

$28.52

Open
Open: 28.25

52 week low

52 week high

$6.75

$43.56

Open

Market cap

$2.24B

Average volume

2.07M

P/E ratio

N/A

Rev. per Employee

N/A

EPS

-3.05

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/itci

MarketWatch News on ITCI

  1. Intra-Cellular Therapies downgraded to neutral from overweight at J.P. Morgan

    8:54 a.m. Jan. 31, 2020

    - Tomi Kilgore

  2. Intra-Cellular Therapies stock price target raised to $65 vs. $29 at Canaccord

    11:48 a.m. Dec. 24, 2019

    - Ciara Linnane

  3. Intra-Cellular Therapies reiterated as buy at Canaccord

    11:48 a.m. Dec. 24, 2019

    - Ciara Linnane

  4. Intra-Cellular Therapies gets FDA approval for schizophrenia treatment

    8:14 a.m. Dec. 23, 2019

    - Ciara Linnane

  5. Intra-Cellular Therapies stock soars 42% premarket

    8:14 a.m. Dec. 23, 2019

    - Ciara Linnane

  6. Intra-Cellular Therapies shares slide 7% after resuming trade following halt.

    7:36 a.m. July 8, 2019

    - Ciara Linnane

  7. Intra-Cellular announces positive results in late-stage trial of treatment for bipolar depression

    7:05 a.m. July 8, 2019

    - Ciara Linnane

  8. Intra-Cellular Therapies and Sol-Gel Technologies halted for news pending

    6:58 a.m. July 8, 2019

    - Ciara Linnane

  9. Intra-Cellular Therapies started at overweight with $25 stock price target at J.P. Morgan

    8:59 a.m. Feb. 26, 2018

    - Tomi Kilgore

  10. Intra-Cellular Therapies upgraded to buy from hold at SunTrust RH

    9:30 a.m. Nov. 9, 2017

    - Tomi Kilgore

  11. Charting the Market

    1:21 a.m. Aug. 26, 2017

    - Barron's Online

  12. Intra-Cellular Therapies price target raised to $16 by SunTrust on positive FDA safety feedback

    8:23 a.m. Aug. 24, 2017

    - Emma Court

  13. Intra-Cellular Therapies shares surge 2% premarket

    8:24 a.m. Aug. 24, 2017

    - Emma Court

  14. Charting the Market

    3:35 a.m. Oct. 1, 2016

    - Barron's Online

  15. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/itci

Other News on ITCI

  1. Cancer advances ignite broad biotech and specialized ETF surge

    4:12 p.m. Sept. 15, 2020

    - Seeking Alpha

  2. Intra-Cellular Therapies prices equity offering at $30

    2:35 a.m. Sept. 11, 2020

    - Seeking Alpha

  3. Company News for Sep 10, 2020

    10:02 a.m. Sept. 10, 2020

    - Zacks.com

  4. ITCI, TRIL, WORK and CODX among midday movers

    12:38 p.m. Sept. 9, 2020

    - Seeking Alpha

  5. TSLA, ACB among premarket gainers

    8:45 a.m. Sept. 9, 2020

    - Seeking Alpha

  6. More info on Intra-Cellular Therapies Q2 results

    1:17 p.m. Aug. 10, 2020

    - Seeking Alpha

  7. 10-Q: INTRA-CELLULAR THERAPIES, INC.

    8:20 a.m. Aug. 10, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  8. Loading more headlines...
/news/pressrelease/company/us/itci

Press Releases on ITCI

  1. Intra-Cellular Therapies Prices Public Offering of Common Stock

    8:30 p.m. Sept. 10, 2020

    - GlobeNewswire

  2. Intra-Cellular Therapies Prices Public Offering of Common Stock

    8:30 p.m. Sept. 10, 2020

    - GlobeNewswire

  3. Wednesday Sector Leaders: Drugs, Trucking Stocks

    12:00 p.m. Sept. 9, 2020

    - MarketNewsVideo.com

  4. Loading more headlines...

Rates »

Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.